Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: Comparison of three types of expression systems

Mutation Research - Genetic Toxicology and Environmental Mutagenesis

Volumn 439, Issue 2, 1999, Pages 287-300

  Kranendonk, Michel ^a,b   Fisher, Charles W ^c,e   Roda, Rita ^a   Carreira, Filipa ^a   Theisen, Patricia ^a   Laires, Antonio ^a,d   Rueff, Jose ^a   Vermeulen, Nico P E ^b   Estabrook, Ronald W ^c  

^a UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^b VU UNIVERSITY AMSTERDAM   (Netherlands)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d UNIVERSIDADE NOVA DE LISBOA   (Portugal)

^e TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Biotransformation; Chemical carcinogen; CYP1A2; E. coli; Human cytochrome P450 1A2; Mutagenicity; NADPH cytochrome P450 reductase

Indexed keywords

2 AMINO 3 METHYLAMIDAZO(4,5) QUINOLINE; AFLATOXIN B1; ANTHRACENE DERIVATIVE; CARCINOGEN; CYTOCHROME P450; ETHOXYRESORUFIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE FERRIHEMOPROTEIN REDUCTASE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; ESCHERICHIA COLI; EXPRESSION VECTOR; INTERMETHOD COMPARISON; MUTAGENIC ACTIVITY; MUTAGENICITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; BLOTTING, WESTERN; CYTOCHROME P-450 ENZYME SYSTEM; ESCHERICHIA COLI; GENETIC VECTORS; HUMANS; MUTAGENICITY TESTS; NADPH-FERRIHEMOPROTEIN REDUCTASE; RATS;

EID: 0033006924     PISSN: 13835718     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5718(98)00193-4     Document Type: Article

References (32)

1. R. Langenbach, P.B. Smith, C. Crespi, Recombinant DNA approaches for the development of metabolic systems used in in vitro toxicology, Mutat. Res. 277 (1992) 251-275.
2. M. Kranendonk, P. Mesquita, A. Laires, N.P.E. Vermeulen, J. Rueff, Expression of human cytochrome P450 1A2 in Escherichia coli: a system for biotransformation and genotoxicity studies of chemical carcinogens, Mutagenesis 3 (1998) 263-269.
3. F.P. Guengerich, Comparison of catalytic selectivity of cytochrome P450 subfamily enzymes from different species, Chem. Biol. Int. 106 (1997) 161-182.
4. F.P. Guengerich, Enzymology of rat liver cytochrome P450, in: F.P. Guengerich (Ed.), Mammalian Cytochromes P450, Vol. 1, CRC Press, Boca Raton, FL, 1987, pp. 1-54.
5. F.P. Guengerich, T. Shimada, Oxidation of toxic and carcionogenic chemicals by human cytochrome P450, Chem. Res. Toxicol. 4 (1991) 391-407.
6. F.J. Gonzalez, Human cytochrome P450: problems and prospects, Trends Pharmacol. Sci. 13 (1992) 346-352.
7. F.J. Gonzalez, H.V. Gelboin, Role of human cytochrome P450 in the metabolic activation of chemical carcinogens and toxins, Drug Chem. Rev. 26 (1994) 165-183.
8. A.R. Goeptar, H. Scheerens, N.P.E. Vermeulen, Oxygen and xenobiotic reductase activities of cytochrome P450, Crit. Rev. Toxicol. 25 (1995) 25-65.
9. F.J. Gonzalez, K.R. Korzekwa, Cytochromes P450 expression systems, Annu. Rev. Pharmacol. Toxicol. 35 (1994) 369-390.
10. F.P. Guengerich, Human cytochrome P450 enzymes, in: P.R. Ortiz de Montellano (Ed.) Cytochrome P450, Plenum, New York, 1995, pp. 473-535.
11. T. Shimada, E.M.J. Gillam, P. Sandhu, Z. Guo, R.H. Tukey, F.P. Guengerich, Activation of procarcinogens by human cytochrome P450 enzymes expressed in Escherichia coli. Simplified bacterial systems for genotoxocity assays, Carcinogenesis 15 (1994) 2523-2529.
12. D.P. Josephy, L.S. Debruin, H.L. Lord, J.N. Oak, D.H. Evans, Z. Guo, M. Dong, F.P. Guengerich, Bioactivation of aromatic amines by recombinant human cytochrome P4501A2 expressed in Ames tester strain bacteria: a substitute for activation by mammalian tissue preparations, Cancer Res. 55 (1995) 799-802.
13. M. Kranendonk, M. Ruas, A. Laires, J. Rueff, Isolation and prevalidation of an Escherichia coli tester strain for genotoxins, in: M.C. Lechner (Ed.), Cytochrome P450, Biochemistry, Biophysics and Molecular Biology, Jonny Libbey Eurotext, Paris, 1994, pp. 741-744.
14. M. Kranendonk, F. Pintado, P. Mesquita, A. Laires, N.P.E. Vermeulen, J. Rueff, MX100, a new Escherichia coli tester strain for use in genotoxicity studies, Mutagenesis 11 (1996) 327-333.
15. M. Kranendonk, J.N.M. Commandeur, A. Laires, J. Rueff, N.P.E. Vermeulen, Characterisation of enzyme activities and cofactors involved in bioactivation and bioinactivation of chemical carcinogens in the tester strains Escherichia coli K12 MX100 and Salmonella typhimurium LT2 TA100, Mutagenesis 12 (1997) 245-254.
16. M. Kranendonk, P. Mesquita, A. Laires, N.P.E. Vermeulen, J. Rueff, Expression of human cytochrome P450 1A2 in Escherichia coli: a new system for biotransformation and genotoxicity studies of chemical carcinogens, FASEB J. 11 (1997) A828, (Abstract).
17. J. Ghrayeb, H. Kimura, M. Takahra, H. Hsiung, Y. Masui, M. Inouye, Secretion cloning vectors in Escherichia coli, EMBO J. 3 (1984) 2442-2473.
18. S. Yamano, T. Oayama, D.W. McBride, J.P. Hardwick, H.V. Gelboin, F.J. Gonzalez, Human NADPH-P450 oxidoreductase: complementary DNA cloning, sequence and vaccinia virus-mediated expression and localization of the CYPOR gene to chromosome 7, Mol. Pharmacol. 35 (1989) 83-88.
19. E.A. Shepard, C.N.A. Palmer, H.J. Segall, I.R. Philips, Quantification of cytochrome P450 reductase gene expression in human tissue, Arch. Biochem. Biophys. 294 (1992) 168-172.
20. M.S. Shet, C.W. Fisher, R.W. Estabrook, The function of recombinant cytochrome P450s in intact Escherichia coli cells: the 17 α-hydroxylation of progesterone and pregnenolone by P450c17, Arch. Biochem. Biophys. 339 (1997) 218-225.
21. M.S. Shet, C.W. Fisher, R.W. Estabrook, Expression, purification and enzymatic properties of a recombinant fusion protein containing human P450 1A2 joined to NADPH-P450 reductase. ISSX Meeting Seattle, Washington, USA, ISSX Proceedings 8, 1995, 362 (Abstract).
22. S. Bauer, J. Shiloach, Maximal exponential growth rate and yield of E. coli obtainable in a bench-scale fermentor, Biotechnol. Bioeng. 16 (1974) 933-941.
23. C.W. Fisher, D.L. Caudle, C. Martin-Wixtrom, L.C. Quattrochi, R.H. Tukey, M.R. Waterman, R.W. Estabrook, High-level expression of functional human cytochrome P450 1A2 in Escherichia coli, FASEB J. 6 (1992) 759-764.
24. M.S. Shet, K. Sathasivan, M. Arlotto, M.C. Mehdy, R.W. Estabrook, Purification, characterization, and cDNA cloning of an NADPH-cytochrome P450 reductase from mung bean, Proc. Natl. Acad. Sci. U.S.A. 90 (1993) 2890-2894.
25. M.D. Burke, S. Thompson, R.J. Weaver, C.R. Wolf, T. Mayer, Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver, Biochem. Pharmacol. 48 (1994) 923-936.
26. M. Macart, L. Gerbaut, An improvement of the Coomassie Blue dye binding method allowing an equal sensitivity to various proteins: application to cerebrospinal fluid, Clin. Chim. Acta 122 (1982) 93-101.
27. D.L. Eaton, E.P. Gallagher, Mechanisms of aflatoxin carcinogenesis, Annu. Rev. Pharmacol. Toxicol. 34 (1994) 135-172.
28. T.K.H. Chang, F.J. Gonzalez, D.J. Waxman, Evaluation of triacetyloleandomycin, a-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochrome P450, Arch. Biochem. Biophys. 311 (1994) 437-442.
29. A. Parikh, M.J. Gilliam, F.P. Guengerich, Drug metabolism by Escherichia coli expressing human cytochrome P450, Nature Biotech. 15 (1997) 784-788.
30. L. Chen, J.T.M. Buters, J.P. Hardwick, S. Tamura, B.W. Penman, F.J. Gonzalez, C.L. Crespi, Coexpression of cytochrome P4502A6 and human NADPH-P450 oxidoreductase in the baculovirus system, Drug Metab. Dispos. 25 (1997) 399-405.
31. H.S. Ramsdell, D.L. Eaton, Species susceptibility to aflatoxin B1 carcinogenesis: comparative kinetics of microsomal biotransformation, Cancer Res. 50 (1990) 615-620.
32. T. Aoyama, S. Yamano, P.S. Guzellian, H.V. Gelboin, F.J. Gonzalez, Five of 12 forms of vaccinia virus-expressed human hepatic CYP metabolically activate aflatoxin B1, Proc. Natl. Acad. Sci. U.S.A. 87 (1990) 4790-4793.